The price-to-earnings ratio for Royalty Pharma stock stands at 16.02 as of Jul 25, 2024. This is based on the current EPS of $1.79 and the stock price of $28.68 per share. A decrease of 58% has been recorded in the PE ratio compared to the average of 38.4 of the last four quarters.
Over the last five years, the average PE ratio of Royalty Pharma has been 52.66. The current 16.02 P/E ratio is 70% lower than the historical average. In the past five years, RPRX's PE ratio peaked in the Dec 2022 quarter at 395.2, with a price of $39.52 and an EPS of $0.1. The Sep 2020 quarter marked the lowest point at 7, with a price of $42.07 and an EPS of N/A.
Maximum annual increase: 1,377.94% in 2022
Maximum annual decrease: -97.2% in 2023
| Year | PE ratio | Change |
|---|---|---|
| 2023 | 11.06 | -97.2% |
| 2022 | 395.2 | 1,377.94% |
| 2021 | 26.74 | -29.48% |
| 2020 | 37.92 | N/A |
| 2019 | N/A | N/A |
| 2018 | N/A | N/A |
| 2017 | N/A | N/A |
Currently, RPRX's PE ratio is lower than the 3-year average.
RPRX's PE ratio stands lower than its peer stocks LLY and ABT.
| Stock name | PE ratio | Market cap |
|---|---|---|
| RPRX Royalty Pharma plc | 16.08 | $17.2B |
| ABT Abbott Laboratories | 32.58 | $183.08B |
| ANIP Ani Pharmaceuticals Inc | 39.04 | $1.33B |
| LLY ELI LILLY & Co | 117.98 | $764.72B |
The price to earnings ratio for RPRX stock as of Jul 25, 2024, stands at 16.02.
The 3-year average price to earnings ratio for RPRX stock is 67.7.
The highest quarterly PE ratio in the last five years has been 395.2 and it was in the Dec 2022 quarter.
RPRX's current price to earnings ratio is 70% below its 5-year historical average.
The P/E ratio is obtained by dividing the latest price of a stock by its trailing twelve months EPS. As of today (Jul 25, 2024), Royalty Pharma's stock price is $28.68. The earnings per share for the trailing twelve months (TTM) ending Mar 2024 is $1.79. Therefore, Royalty Pharma's PE ratio for today is 16.02. PE RATIO(16.02) = STOCK PRICE($28.68) / TTM EPS($1.79)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.